I don't know about the fall or autumn be it the southern or...

I don't know about the fall or autumn be it the southern or northern hemisphere, USA or Australia but the top line results from P2 will not be received until 2H 2025 at the earliest. Recruitment ongoing til end Dec 2024, 24 weeks of trialling plus 8-12 weeks for the results to be analyzed, peer reviewed and released.

In the meantime my reading is the level of risk re failure is very low (10 to 15% max). Digest the fact that P1 was not just a 12 patient longitudinal trial but 4 separate trials of 6 patients each and each separate trial concluded with outstanding results as was hoped for with an increasing dosage increased, no inconsistent results, no SAEs, no deaths, all breathing and swallowing independently, all continuing on the OLE. No, zero, zilch other trials have shown such outstanding results so as shareholders we understand the substantial de-risking that has taken place while Mr Market and BP play catch up and come to terms with such amazing results. Of course being a clinical biotechnology company based in Australia, listed on the ASX with little to no marketing and promotion prior to 6-months ago then the under valuation is to be expected

Eventually the SP will reflect the blockbuster nature than MPL is....without question, just keep your patient hat on and as NZT would say....HOLD, HOLD, HOLD OR IF NOT MAKE 'EM PAY!!!